Nagesh K. Mahanthappa, PhD, MBA
CEO & President

Dr. Nagesh K. Mahanthappa is the founding employee of Scholar Rock and has served as a director and President and Chief Executive Officer since October 2012. Prior to Scholar Rock, from February 2007 to May 2012, Nagesh was a founding employee and Vice President, Corporate Development and Operations at Avila Therapeutics, Inc. (acquired by Celgene Corporation in March 2012). Previously, from August 2002 to February 2007, he served in roles of increasing responsibility at Alnylam Pharmaceuticals, Inc., most recently as Vice President, Scientific and Strategic Development. He was also a founder of TwistDx, Inc. a DNA diagnostics company acquired by Inverness Medical Innovations, Inc. in 2010 (now a division of Abbott). Nagesh received his Ph.D. in Neurobiology from the California Institute of Technology, and completed his post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. Nagesh received his M.B.A. from the F.W. Olin Graduate School of Management at Babson College and his B.A. in Biology and Chemistry from the University of Colorado, Boulder.

Elan Z. Ezickson, JD
Chief Operating Officer & Head of Corporate Development

Mr. Elan Z. Ezickson has served as Chief Operating Officer and Head of Corporate Development since August 2014 and is responsible for overseeing corporate development, operations and administration, and execution of Scholar Rock’s corporate strategy. Prior to joining Scholar Rock, Elan served most recently as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. From 1994 to 2003, he worked at Biogen Inc. in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Elan holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law.

Yung H. Chyung, MD
Chief Medical Officer

Dr. Yung H. Chyung has served as Chief Medical Officer since February 2016 and leads the clinical development of pipeline candidates and medical affairs. Prior to joining Scholar Rock, Yung served in roles of increasing responsibility at Dyax Corp. (acquired by Shire Plc in January 2016) from 2011 to February 2016, most recently serving as Vice President of Medical Research, where he was responsible for clinical research and medical affairs. From 2010 to 2011, he worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple rare disease programs. Yung earned his M.D. from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an A.B. in Biochemical Sciences from Harvard College.

Alan J. Buckler, PhD
Chief Scientific Officer

Dr. Alan J. Buckler has served as Chief Scientific Officer since November 2016 and is responsible for research, discovery and preclinical development. Prior to joining Scholar Rock, Alan served as Vice President, Cell and Protein Sciences at Biogen Inc. from 2014 to 2016. From 2005 to 2014, Alan served as Director, Developmental and Molecular Pathways in the Novartis Institutes for Biomedical Research. Prior to Novartis, Alan served as the Chief Scientific Officer of Ardais Corporation from 1999 to 2004 and as Vice President of Molecular Genetics at Sequana Therapeutics/Axys Pharmaceuticals from 1996 to 1999. Prior to joining the private sector, Alan served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School from 1991 to 1996. Alan received his A.B. in Biology from the University of Chicago, Ph.D. in Microbiology from the Boston University School of Medicine, and completed his post-doctoral training at the Center for Cancer Research, Massachusetts Institute of Technology.

Rhonda Chicko
Chief Financial Officer

Ms. Rhonda Chicko has served as Chief Financial Officer since April 2018. She is an accomplished financial executive with over 25 years of experience in enhancing performance and developing systems, processes and procedures to streamline operations for start-ups and high growth companies. Prior to joining Scholar Rock, Rhonda was most recently the Vice President of Finance at Editas Medicine where she oversaw finance, accounting, tax, treasury and insurance. Prior to Editas, Rhonda held positions of increasing responsibility at Ironwood Pharmaceuticals, including Senior Director, Finance and Tax. Earlier in her career, Rhonda provided consulting and advisory services through her own CPA practice to clients ranging from start-ups to established public companies. Previously, she served as Controller at Wellington Management Company, LLP and began her career in public accounting at PricewaterhouseCoopers, LLP. Rhonda is a Certified Public Accountant, and holds a M.S. in taxation from Bentley University and a B.S. in accounting from Le Moyne College.

Gregory J. Carven, PhD
Senior Vice President, Antibody Discovery and Protein Sciences

Dr. Gregory J. Carven has served as Senior Vice President, Antibody Discovery and Protein Sciences since March 2018 after joining Scholar Rock in 2014 and directs Scholar Rock’s discovery, design, and manufacturing of therapeutic antibodies. He is a recognized leader, with more than 15 years of experience in the discovery and development of antibody therapeutics. Gregory was recognized for the invention of Keytruda® (pembrolizumab) with his receipt of an award for “Inventor of the Year” in 2016 by the Intellectual Property Owners Education Foundation. Most recently, he was head of hybridoma research within Pfizer’s Global Biotherapeutics Technologies. Prior to joining Pfizer, Gregory held positions of increasing responsibility at Merck Research Laboratories (formerly Schering Plough Research Institute and Organon Biosciences), and was a scientist at Phylogix, Inc. Gregory received his Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, and continued his research at the University of Massachusetts Medical School.

Heather Faulds
Vice President, Regulatory Affairs

Ms. Heather Faulds has served as Vice President, Regulatory Affairs since September 2017 and is responsible for managing the regulatory strategy for Scholar Rock’s pipeline of drug candidates. She has over 15 years of regulatory experience at innovative biotechnology companies across all stages of development, from first-in-human studies to product approvals and product label expansions. She most recently served as Senior Director of Regulatory Affairs at Biogen. Prior to working at Biogen, Heather was Manager, Regulatory Affairs and CMC Operations at Oxigene, Inc. Heather earned her M.S. degree in Drug Regulatory Affairs and Health Policy at the Massachusetts College of Pharmacy. She also holds a B.S. in Biology from the University of Albany.

Junlin Ho, JD
Vice President, Head of Corporate Legal

Ms. Junlin Ho has served as Vice President, Head of Corporate Legal since March 2018, overseeing all corporate legal and compliance matters. She has over 10 years of experience leading and advising on various legal aspects associated with corporate governance, business development, financing, securities law, commercial product planning and launches, and international operations. Prior to Scholar Rock, she served as Associate General Counsel at Foundation Medicine where she helped lead the team in support of that company’s initial public offering and was a member of the team that negotiated a major strategic partnership. Additionally, Junlin served as Associate General Counsel, Corporate at Ziopharm Oncology and was a corporate attorney in the life sciences practice at the law firm Ropes & Gray LLP from 2008 to 2013. She received her S.B. from Massachusetts Institute of Technology in Civil Engineering and City Planning and J.D. from University of Chicago Law School.

Ryan Iarrobino
Vice President, Clinical Operations

Mr. Ryan Iarrobino has served as Vice President, Clinical Operations since October 2017. He has over 18 years of clinical development experience working at contract research organization and biotechnology companies, with a focus on rare diseases. Prior to joining Scholar Rock, Ryan served as Head of Clinical Operations at Syntimmune, Inc., and was previously Vice President, Clinical Development at Dyax Corporation. Before building and leading internal clinical operations and clinical data management teams, Ryan served clients in his roles at the CROs, Averion International Corp. (now Icon, Plc) and Parexel International. Ryan received his B.A. from the University of Maine.

Erin Moore
Vice President, Finance

Ms. Erin Moore has served as Vice President, Finance since October 2018. She has over 15 years of corporate accounting experience with a proven record of developing and implementing financial controls and streamlining accounting processes. Prior to Scholar Rock, she served as Controller, Senior Director of Accounting at Synlogic, Inc. where she built the accounting department and established processes and procedures to support accounting operations for a rapidly growing company and its public offerings. Prior to Synlogic, Inc. she served as Director of Accounting at Abiomed, Inc. from 2015 to 2016 and GI Dynamics, Inc. from 2012 to 2015. From 2006 to 2012, Erin held various roles of increasing responsibility in accounting at Ironwood Pharmaceuticals. Erin is a Certified Public Accountant and holds a M.S. in Accounting from Bentley College, a M.S. in Environmental Management and Economics from Johns Hopkins University and a B.A. from Clark University.

Atsuko Polzin, PhD, JD
Vice President, Intellectual Property

Dr. Atsuko Polzin has served as Vice President, Intellectual Property since March 2018 after joining Scholar Rock in September 2016. She has over 12 years of experience in building and managing complex intellectual property portfolios. Prior to joining Scholar Rock, Atsuko served as Head, Intellectual Property and Senior Counsel R&D at Seqirus, formerly Novartis Influenza Vaccines. Prior to the divestiture of Novartis Vaccines, she was responsible for Novartis’ global strategy and management of patent portfolios related to adjuvants and viral vaccines, and provided legal counsel on litigation, licensing and government contracts. Atsuko previously practiced Intellectual Property law in the life science group at the law firms Choate, Hall and Stewart LLP, as well as Wolf, Greenfield & Sacks, P.C.. She earned her J.D. degree from Suffolk University Law School and holds a Ph.D. in Neuroscience from Tufts University.

Dodzie Sogah, PhD
Vice President, Corporate Development and Strategy

Dr. Dodzie Sogah has served as Vice President, Corporate Development and Strategy since March 2018 and joined Scholar Rock in 2016. He has significant experience in leading scientific, corporate, and business strategy at early and late-stage biotechnology companies. Prior to joining Scholar Rock, Dodzie was Senior Director of Corporate and Business Development at Vertex Pharmaceuticals, where he was responsible for leading the sourcing, evaluation, and negotiation of licensing and acquisition opportunities. Prior to Vertex, Dodzie worked at Alnylam Pharmaceuticals in program and alliance management, and was a management consultant at Bain and Company. Dodzie received his Ph.D. in Cell Biology from Harvard Medical School. He also holds an A.B. in Biochemical Sciences and M.A. in Molecular and Cellular Biology from Harvard University.

Catherine Hu
Executive Director, Investor Relations and Corporate Communications

Ms. Catherine Hu has served as Executive Director, Investor Relations and Corporate Communications since March 2018 and is responsible for leading external and internal communications. She has over 13 years of investment and communications experience in the biopharmaceutical sector. Prior to joining Scholar Rock, Catherine was Director of Investor Relations at Alexion Pharmaceuticals, Inc, where she played a key role in managing strategic, corporate and product communications with investors. Prior to Alexion, she spent over a decade as a sell-side analyst at Bank of America Merrill Lynch, Barclays, Deutsche Bank and Credit-Suisse and covered biotechnology, pharmaceuticals and medical devices. Catherine received a B.S. in Finance and International Business from the Stern School of Business at New York University.

“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2018 Scholar Rock All Rights Reserved.
Back to Top

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel